While there are now effective vaccines against infection with the early strains of SARS-CoV-2, prior to their development one of the strategies devised for treating Acute Respiratory Distress Syndrome (ARDS) associated with the SARS-CoV-1 was administration of a recombinant ACE2 12, 26. Here, ACE2 is linked to acute respiratory distress syndrome.